Date published: 2026-8-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

α-sarcoglycan CRISPR/Cas9 KO Plasmid (h): sc-403837

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • α-sarcoglycan CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the α-sarcoglycan genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: α-sarcoglycan Antibody (D-7): sc-271321
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    α-sarcoglycan CRISPR/Cas9 KO Plasmid (h)

    sc-403837
    20 µg
    $397.00

    Overview

    SGCA encodes human α-sarcoglycan, a core component of the sarcoglycan subcomplex within the dystrophin-associated glycoprotein complex that stabilizes the muscle cell membrane during contraction. By linking the extracellular matrix to the cortical cytoskeleton, α-sarcoglycan supports sarcolemmal integrity, mechanotransduction, and organization of membrane microdomains involved in muscle homeostasis. Disruption of SGCA perturbs dystrophin complex assembly, increases susceptibility to contraction-induced damage, and alters downstream stress and inflammatory signaling in skeletal and cardiac muscle. Loss-of-function variants are associated with limb-girdle muscular dystrophy phenotypes, making SGCA a widely used target for modeling muscle membrane instability and related pathways.

    α-sarcoglycan CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SGCA gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SGCA together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SGCA open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish α-sarcoglycan protein expression.

    This CRISPR knockout system enables efficient generation of SGCA-deficient cell models for investigation of α-sarcoglycan signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting SGCA exon(s) critical for α-sarcoglycan function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple SGCA genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by α-sarcoglycan CRISPR/Cas9 KO Plasmid (h) and α-sarcoglycan CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SGCA locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by α-sarcoglycan HDR Plasmid (h) and α-sarcoglycan HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SGCA homology arms to support homology-directed repair at defined SGCA target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.